Tideglusib (NP-12, NP031112) is a potent and irreversible small molecule glycogen synthase kinase 3 (GSK-3) inhibitor. |
Read full article at Wikipedia
|
InChI=1S/C19H14N2O2S/c22- 18- 20(13- 14- 7- 2- 1- 3- 8- 14) 19(23) 24- 21(18) 17- 12- 6- 10- 15- 9- 4- 5- 11- 16(15) 17/h1- 12H,13H2 |
PMJIHLSCWIDGMD-UHFFFAOYSA-N |
O=C1N(C=2C3=C(C=CC=C3)C=CC2)SC(=O)N1CC4=CC=CC=C4 |
|
EC 2.7.11.26 (tau-protein kinase) inhibitor
An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of tau-protein kinase inhibitor (EC 2.7.11.26).
apoptosis inducer
Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
|
|
neuroprotective agent
Any compound that can be used for the treatment of neurodegenerative disorders.
anti-inflammatory agent
Any compound that has anti-inflammatory effects.
|
|
View more via ChEBI Ontology
4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione
|
tideglusib
|
WHO MedNet
|
tideglusib
|
WHO MedNet
|
tidéglusib
|
WHO MedNet
|
tideglusibum
|
WHO MedNet
|
NP 031112
|
ChemIDplus
|
NP-031112
|
DrugBank
|
NP-12
|
DrugBank
|
NP031112
|
DrugBank
|
Nypta
|
ChEBI
|
Zentylor
|
ChEBI
|
865854-05-3
|
CAS Registry Number
|
ChemIDplus
|
17522320
|
PubMed citation
|
Europe PMC
|
22936007
|
PubMed citation
|
Europe PMC
|
24488721
|
PubMed citation
|
Europe PMC
|
24532007
|
PubMed citation
|
Europe PMC
|
25537011
|
PubMed citation
|
Europe PMC
|
26289787
|
PubMed citation
|
Europe PMC
|
26398371
|
PubMed citation
|
Europe PMC
|
27378458
|
PubMed citation
|
Europe PMC
|
27490211
|
PubMed citation
|
Europe PMC
|
28982059
|
PubMed citation
|
Europe PMC
|
29388174
|
PubMed citation
|
Europe PMC
|
29431064
|
PubMed citation
|
Europe PMC
|
29603837
|
PubMed citation
|
Europe PMC
|
30574063
|
PubMed citation
|
Europe PMC
|
30666199
|
PubMed citation
|
Europe PMC
|
30965670
|
PubMed citation
|
Europe PMC
|
31156177
|
PubMed citation
|
Europe PMC
|
32195836
|
PubMed citation
|
Europe PMC
|
|